ICOVIR-5 shows E2F1 addiction and potent antiglioma effect in vivo

Cancer Research

Volumn 67, Issue 17, 2007, Pages 8255-8263

  Alonso, Marta M ^a   Cascallo, Manel ^b   Gomez Manzano, Candelaria ^a   Jiang, Hong ^a   Bekele, B Nebiyou ^a   Perez Gimenez, Anna ^b   Lang, Frederick F ^a   Piao, Yuji ^a   Alemany, Ramon ^b   Fueyo, Juan ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b CATALAN INSTITUTE OF ONCOLOGY   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ONCOLYTIC ADENOVIRUS; RETINOBLASTOMA PROTEIN; TRANSCRIPTION FACTOR E2F1;

ADENOVIRUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CONTROLLED STUDY; DRUG EFFECT; GENE DELETION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INTERACTION; VIROGENESIS;

ADENOVIRIDAE; ADENOVIRUS E1A PROTEINS; ANIMALS; E2F1 TRANSCRIPTION FACTOR; GENE EXPRESSION REGULATION, VIRAL; GLIOMA; HUMANS; MICE; MICE, NUDE; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; RETINOBLASTOMA PROTEIN; TREATMENT OUTCOME; TUMOR CELLS, CULTURED; VIRUS REPLICATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 34548558821     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-06-4675     Document Type: Article

References (37)

1. Stupp R , Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352:987-96.
2. Reardon DA, Rich JN, Friedman HS, Bigner DD. Recent advances in the treatment of malignant astrocytoma. J Clin Oncol 2006;24:1253-65.
3. Ueki K, Ono Y, Henson JW, et al. CDKN2/p16 or RB alterations occur in the majority of glioblastomas and are inversely correlated. Cancer Res 1996;56:150-3.
4. Hahn WC, Weinberg RA. Rules for making human tumor cells. N Engl J Med 2002;347:1593-603.
5. O'Shea CC. Viruses - seeking and destroying the tumor program. Oncogene 2005;24:7640-55.
6. Berk AJ. Functions of adenovirus E1A. Cancer Surv 1986;5:367-87.
7. Whyte P, Williamson NM, Harlow E. Cellular targets for transformation by the adenovirus E1A proteins. Cell 1989;56:67-75.
8. Fueyo J, Gomez-Manzano C, Alemany R, et al. A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo. Oncogene 2000;19:2-12.
9. Heise C, Hermiston T, Johnson L, et al. An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy. Nat Med 2000;6:1134-9.
10. Krasnykh V, Dmitriev I, Navarro JG, et al. Advanced generation adenoviral vectors possess augmented gene transfer efficiency based upon coxsackie adenovirus receptor-independent cellular entry capacity. Cancer Res 2000;60:6784-7.
11. Suzuki K, Fueyo J, Krasnykh V, et al. A conditionally replicative adenovirus with enhanced infectivity shows improved oncolytic potency. Clin Cancer Res 2001;7:120-6.
12. Fueyo J, Alemany R, Gomez-Manzano C, et al. Preclinical characterization of the antiglioma activity of a tropism-enhanced adenovirus targeted to the retinoblastoma pathway. J Natl Cancer Inst 2003;95:652-60.
13. White E. Regulation of the cell cycle and apoptosis by the oncogenes of adenovirus. Oncogene 2001;20:7836-46.
14. Berk AJ. Recent lessons in gene expression, cell cycle control, and cell biology from adenovirus. Oncogene 2005;24:7673-85.
15. Johnson L, Shen A, Boyle L, et al. Selectively replicating adenoviruses targeting deregulated E2F activity are potent, systemic antitumor agents. Cancer Cell 2002;1:325-37.
16. Jakubczak JL, Ryan P, Gorziglia M, et al. An oncolytic adenovirus selective for retinoblastoma tumor suppressor protein pathway-defective tumors: dependence on E1A, the E2F-1 promoter, and viral replication for selectivity and efficacy. Cancer Res 2003;63:1490-9.
17. Ryan PC, Jakubczak JL, Stewart DA, et al. Antitumor efficacy and tumor-selective replication with a single intravenous injection of OAS403, an oncolytic adenovirus dependent on two prevalent alterations in human cancer. Cancer Gene Ther 2004;11:555-69.
18. Jones N, Shenk T. Isolation of deletion and substitution mutants of adenovirus type 5. Cell 1978;13:181-8.
19. Hong SS, Gay B, Karayan L, Dabauvalle MC, Boulanger P. Cellular uptake and nuclear delivery of recombinant adenovirus penton base. Virology 1999;262:163-77.
20. Majem M, Cascallo M, Bayo-Puxan N, et al. Control of E1A under an E2F-1 promoter insulated with the myotonic dystrophy locus insulator reduces the toxicity of oncolytic adenovirus Ad-Δ24RGD. Cancer Gene Ther 2006;13:696-705.
21. Johnson DG, Ohtani K, Nevins JR. Autoregulatory control of E2F1 expression in response to positive and negative regulators of cell cycle progression. Genes Dev 1994;8:1514-25.
22. Gomez-Manzano C, Fueyo J, Kyritsis AP, et al. Characterization of p53 and p21 functional interactions in glioma cells en route to apoptosis. J Natl Cancer Inst 1997;89:1036-44.
23. Fueyo J, Gomez-Manzano C, Yung WK, Kyritsis AP. The functional role of tumor suppressor genes in gliomas: clues for future therapeutic strategies. Neurology 1998;51:1250-5.
24. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCRand the 2(-ΔΔC(T)) method. Methods 2001;25:402-8.
25. Lal S, Lacroix M, Tofilon P, et al. An implantable guide-screw system for brain tumor studies in small animals. J Neurosurg 2000;92:326-33.
26. Falkeholm L, Grant CA, Magnusson A, Mèoller E. Xylene-free method for histological preparation: a multicentre evaluation. Lab Invest 2001;81:1213-21.
27. Johnson DG, Schwarz JK, Cress WD, Nevins JR. Expression of transcription factor E2F1 induces quiescent cells to enter S phase. Nature 1993;365:349-52.
28. Sherr CJ. The Pezcoller lecture: cancer cell cycles revisited. Cancer Res 2000;60:3689-95.
29. Sherr CJ, McCormick F. The RB and p53 pathways in cancer. Cancer Cell 2002;2:103-12.
30. Adams PD, Kaelin WG, Jr. Transcriptional control by E2F. Semin Cancer Biol 1995;6:99-108.
31. Sellers WR, Rodgers JW, Kaelin WG, Jr. A potent transrepression domain in the retinoblastoma protein induces a cell cycle arrest when bound to E2F sites. Proc Natl Acad Sci U S A 1995;92:11544-8.
32. Parr MJ, Manome Y, Tanaka T, et al. Tumor-selective transgene expression in vivo mediated by an E2F-responsive adenoviral vector. Nat Med 1997;3:1145-9.
33. Alonso MM, Fueyo J, Shay JW, et al. Expression of transcription factor E2F1 and telomerase in glioblastomas: mechanistic linkage and prognostic significance. J Natl Cancer Inst 2005;97:1589-600.
34. Dmitriev I, Krasnykh V, Miller CR, et al. An adenovirus vector with genetically modified fibers demonstrates expanded tropism via utilization of a coxsackievirus and adenovirus receptor-independent cell entry mechanism. J Virol 1998;72:9706-13.
35. Paulus W, Baur I, Schuppan D, Roggendorf W. Characterization of integrin receptors in normal and neoplastic human brain. Am J Pathol 1993;143:154-63.
36. Riemenschneider MJ, Mueller W, Betensky RA, Mohapatra G, Louis DN. In situ analysis of integrin and growth factor receptor signaling pathways in human glioblastomas suggests overlapping relationships with focal adhesion kinase activation. Am J Pathol 2005;167:1379-87.
37. Working PK, Lin A, Borellini F. Meeting product development challenges in manufacturing clinical grade oncolytic adenoviruses. Oncogene 2005;24:7792-801.